System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Orlando Guntinas-Lichius is an expert in Otolaryngology at Jena University Hospital (Germany). As of October 2026, ScienceLeadR ranks Orlando Guntinas-Lichius in the top 1% of experts worldwide for Facial Paralysis, Pharyngeal Diseases and Carcinoma. Orlando Guntinas-Lichius has authored 1,121 publications, the most recent in 2026, and is an investigator in 15 clinical trials, 5 of them ongoing. SLR score: 3,376 (community average: 125). How the SLR is computed.

LeadR Profile

Orlando Guntinas-Lichius Jena University Hospital Germany
3 376 ScienceLeadR Reputation 3376

Unlock

Register Login
Network Map

Otolaryngology

Subspecialties: Oncology - Neurology - Pediatrics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1993 - 2026
Source: PubMed

Jena University Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1121

Citations

Citations: 16 825 1st author: 89 Last author: 407 Unique author: 52

Main journals

Laryngorhinootologie 335
Eur Arch Otorhinolaryngol 67
HNO 60
Laryngoscope 41
Springer eBooks 37

Best Journals

N Engl J Med 10
Lancet Oncol 2
Ann Oncol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Cutaneous Leiomyosarcoma of the Head and Neck: Appreciation of a More Indolent Biological Behavior and Implications for Its Management.
PMID 42885217 — leiomyosarcoma, sarcoma		Head Neck20260
The Impact of Comorbidity on Severe Procedure-Coded Inpatient Events in Head and Neck Cancer and Thyroid Cancer Hospitalizations in Germany: A Nationwide DRG Analysis, 2005-2021.
PMID 42738380 — radiotherapy, comorbidity, hospitalization, neoplasms, thyroid gland, drug therapy, aged, thyroid neoplasms, head and neck neoplasms, diagnosis-related groups, therapeutics, mouth, pharynx, chemotherapy		Cancers (Basel)20260
A systematic review of international/national guidelines for the management of nasopharyngeal carcinoma: Convergence and divergence of recommendations.
PMID 42726913 — radiotherapy, neoplasms, nasopharyngeal carcinoma, therapeutics		Cancer20260
Transoral Robotic Surgery in Head and Neck Oncology: A Scoping Review of Evidence, Technological Advancements, and Future Trajectories.
PMID 42604589 — oropharyngeal neoplasms, hemorrhage, neoplasms, records		J Surg Oncol20260
Sliding hiatal hernia detected by transnasal esophagogastroscopy is associated with poorer treatment response in reflux-associated globus sensation.
PMID 42586997 — hernia, sensation, hernia, hiatal, globus sensation, therapeutics		Sci Rep20260

Clinical Studies 15

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3

By phase:

Phase 2 8
Phase 3 5
Phase 1 1
Phase 1/Phase 2 1

By status:

Completed 8
Recruiting 5
Terminated 2

By type:

Interventional 15

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 1
multicentric5to9 2
multicentricup10 12

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Nivolumab in combination with cisplatin and 5 fluorouracil as induction therapy in children and adults with EBV positive nasopharyngeal carcinoma
2022-500676-59-00 — fluorouracil, herpesvirus 4, human, nivolumab, nasopharyngeal carcinoma, therapeutics, child, carcinoma		Phase 2Recruiting2022
A Phase 3 study of NBTXR3 with or without cetuximab in LA HNSCC
2024-520386-31-00 — radiotherapy, cells, cetuximab, carcinoma, squamous cell, drug therapy, aged, squamous cell carcinoma of head and neck, chemotherapy, carcinoma, head, neck		Phase 3Recruiting2025
European Larynx Organ Preservation Study (ELOS)
2022-502751-61-00 — cells, larynx, organ preservation, docetaxel, induction chemotherapy, carcinoma, squamous cell, laryngectomy, neoplasms, hypopharyngeal neoplasms, biopsy, drug therapy, therapeutics, tissues, chemotherapy, carcinoma		Phase 2Recruiting2024
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST NP)
NCT06338995 — safety, adrenal cortex hormones, polyps, therapeutics, nasal polyps, rhinosinusitis		Phase 3Recruiting2024
European Larynx Organ Preservation Study (ELOS) MK 3475 C44
NCT06137378 — cells, laryngeal diseases, disease-free survival, larynx, organ preservation, docetaxel, induction chemotherapy, carcinoma, squamous cell, laryngectomy, laryngeal neoplasms, neoplasms, hypopharyngeal neoplasms, drug therapy, immune checkpoint inhibitors, squamous cell carcinoma of head and neck, neoadjuvant therapy, therapeutics, chemotherapy, carcinoma		Phase 2Recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS